Vestal Point Capital LP Makes New $1.73 Million Investment in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Vestal Point Capital LP purchased a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 40,000 shares of the company’s stock, valued at approximately $1,731,000. Vestal Point Capital LP owned 0.14% of Establishment Labs at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Establishment Labs by 1.8% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 35,236 shares of the company’s stock valued at $1,525,000 after purchasing an additional 632 shares during the period. Hood River Capital Management LLC acquired a new stake in shares of Establishment Labs during the 2nd quarter valued at approximately $43,000. California State Teachers Retirement System boosted its stake in shares of Establishment Labs by 14.5% during the 1st quarter. California State Teachers Retirement System now owns 17,096 shares of the company’s stock worth $870,000 after acquiring an additional 2,167 shares in the last quarter. Nkcfo LLC acquired a new stake in shares of Establishment Labs in the 2nd quarter worth approximately $227,000. Finally, Kornitzer Capital Management Inc. KS increased its stake in Establishment Labs by 2.5% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 248,435 shares of the company’s stock valued at $10,750,000 after purchasing an additional 6,050 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on ESTA. JPMorgan Chase & Co. decreased their target price on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Stephens reiterated an “overweight” rating and issued a $68.00 price objective on shares of Establishment Labs in a research report on Wednesday, August 7th. BTIG Research raised their target price on shares of Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Citigroup upped their price target on shares of Establishment Labs from $45.00 to $50.00 and gave the company a “neutral” rating in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $60.60.

Establishment Labs Stock Up 1.1 %

NASDAQ:ESTA opened at $46.07 on Friday. Establishment Labs Holdings Inc. has a 12-month low of $22.05 and a 12-month high of $60.12. The company’s 50-day moving average is $43.13 and its two-hundred day moving average is $44.99. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.